Clinical Trials Logo

Peripheral Neuropathy clinical trials

View clinical trials related to Peripheral Neuropathy.

Filter by:

NCT ID: NCT04343911 Completed - Clinical trials for Postoperative Complications

Postoperative Peripheral Neuropathy After Laparoscopic Colorectal Surgery

Start date: November 1, 2014
Phase: N/A
Study type: Interventional

This prospective cohort study of patients undergoing colorectal surgery positioned conventionally with shoulder braces was performed. After initial results the implementation of the Pink Pad ® took place in order to compare the two groups. This study favours Pink Pad over conventional positioning concerning postoperative neuropathy.

NCT ID: NCT04340999 Completed - Clinical trials for Peripheral Neuropathy

Electrophysiological Evaluation of Motor Dysfunction in Liver Cirrhotic Patients

Start date: August 1, 2018
Phase:
Study type: Observational

cross sectional observational study, aimed to assess the electrophysiological function of the motor units in liver cirrhotic patients.

NCT ID: NCT04242797 Completed - Clinical trials for Peripheral Neuropathy

Central Mechanisms of Calmare: an fMRI Trial

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

Pilot one-treatment and extended 10-treatment studies are carried out on participants with peripheral neuropathy comparing traditional TENS and Calmare stimulation protocols using a double-blind apparatus. Resting fMRI scans are obtained before and after the treatment, as well as after most of the pain has returned.

NCT ID: NCT04117269 Recruiting - Diabetic Foot Ulcer Clinical Trials

External Shoe Lift to Improve Healing and Adherence in Patients With Diabetic Foot Ulcers

Start date: November 15, 2019
Phase: N/A
Study type: Interventional

Previous researches hipothesize that imposed limb-length discrepancies may discourage adherence in patients with active diabetic foot ulcer and using offloading devices. Our hipothesis is that the use of an external shoe lift contralaterally to the affected foot may improve adherence to offloading devices and improve healing.

NCT ID: NCT04064996 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effectiveness of Foot Exercise People With Type 2 Diabetes

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study will to investigate the effect of foot exercises in patients with type 2 diabetic and peripheral neuropathy. Subjects will be randomly allocated to either the control or intervention group. Data will be collected using investigator-developed forms: patient information form and the diabetic foot exercises log. Patients in the intervention group will be received standard treatment and performed foot exercises for three times a week 8 weeks; the control group will be received standard treatment but no exercises. The intervention and control groups will be examined and measured at the 4th and 8th weeks.

NCT ID: NCT04005287 Completed - Clinical trials for Peripheral Neuropathy

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in subjects with T2DM with peripheral neuropathy.

NCT ID: NCT03965884 Completed - Clinical trials for Peripheral Neuropathy

Clinical Effects of Lumbal Stabilization Exercises and Connective Tissue Massage on Neuropathic Pain, Functional Capacity and Quality of Life

Start date: April 18, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the efficacy of connective tissue massage and lumbar stabilization exercise treatment on pain severity, functional capacity and quality of life in those who have experienced peripheral neuropathy

NCT ID: NCT03913689 Recruiting - Chronic Pain Clinical Trials

StimRouter Registry Clinical Protocol

Start date: June 26, 2019
Phase:
Study type: Observational [Patient Registry]

This Registry study will prospectively evaluate the long-term effectiveness, safety, and tolerability of the StimRouter Neuromodulation System, along with evaluating the technical performance of StimRouter, surgical outcomes, health-related quality of life, concomitant medical use, and subject's impression of improvement.

NCT ID: NCT03881748 Withdrawn - Clinical trials for Peripheral Neuropathy

Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy

Start date: October 2021
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to learn if one acupuncture treatment approach is more effective than another in helping to relieve chemo-therapy induced neuropathy in cancer patients. If eligible to take part in this study, participants will be randomly assigned to 1 of 2 groups - group 1 participants will receive traditional acupuncture treatments 2 times a week for a total of 20 sessions. Group 2 participants will have acupuncture sessions with electrical stimulation 2 times a week for a total of 20 sessions.

NCT ID: NCT03830762 Completed - Clinical trials for Peripheral Neuropathy

Xanamemâ„¢ in Healthy Elderly Subjects

XanaHES
Start date: January 21, 2019
Phase: Phase 1
Study type: Interventional

Xanamemâ„¢ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Alzheimer's disease. The XanaHES study is testing the safety and tolerability of Xanamem. It is planned to enrol approximately 84 participants, male and female aged from 50 to 75 who are in good health, in the study at 1 centre in Australia. The XanaHES Phase I study is a single-blind study. Subjects will be randomised to receive either 20mg once daily Xanamem or Placebo in cohort 1. Once all subjects have completed the study treatment of 12 weeks, a dose escalation committee will decide if a new cohort, cohort 2, with 30mg once daily vs placebo is started.